2025
Validity of Diagnostic Codes and Laboratory Tests to Identify Cholangiocarcinoma and Its Subtypes
Ferrante N, Hubbard R, Weinfurtner K, Mezina A, Newcomb C, Furth E, Bhattacharya D, Njei B, Taddei T, Singal A, Hoteit M, Park L, Kaplan D, Re V. Validity of Diagnostic Codes and Laboratory Tests to Identify Cholangiocarcinoma and Its Subtypes. Pharmacoepidemiology And Drug Safety 2025, 34: e70154. PMID: 40328444, PMCID: PMC12055315, DOI: 10.1002/pds.70154.Peer-Reviewed Original ResearchConceptsPositive predictive valueVeterans Health AdministrationExtrahepatic cholangiocarcinomaValidity of diagnostic codesInternational Classification of Diseases for OncologyUS Veterans Health AdministrationConfidence intervalsPharmacoepidemiological studiesICD-O-3Days of diagnosisVA dataHealth AdministrationIntrahepatic cholangiocarcinomaDiagnostic codesHistology codesCholangiocarcinomaUnique patientsInclusion criteriaCholangiocarcinoma subtypesTopography codesPredictive valuePatientsEvaluate medicationsSubtypesEvaluate determinantsTHE OVERTUBE-ASSISTED PERCUTANEOUS PULL GASTROSTOMY TUBE PLACEMENT IS SAFE IN PATIENTS WITH HEAD AND NECK CANCER
Protiva P, Ketwaroo G, Njei B, Saha S. THE OVERTUBE-ASSISTED PERCUTANEOUS PULL GASTROSTOMY TUBE PLACEMENT IS SAFE IN PATIENTS WITH HEAD AND NECK CANCER. Gastrointestinal Endoscopy 2025, 101: s233. DOI: 10.1016/j.gie.2025.03.403.Peer-Reviewed Original ResearchIncreasing Incidence, Cost, and Mortality of AKI and HRS in Hospitalized Patients With Cirrhosis.
Goyes D, Njei B, Lim JK. Increasing Incidence, Cost, and Mortality of AKI and HRS in Hospitalized Patients With Cirrhosis. JAMA Netw Open 2025, 8: e2511822. PMID: 40397449, DOI: 10.1001/jamanetworkopen.2025.11822.Peer-Reviewed Original ResearchSocioeconomic and demographic disparities in the impact of digestive diseases in the middle East and North Africa (MENA) region
Al Ta’ani O, Al-Ajlouni Y, Lahoud C, Almasaid S, Alhalalmeh Y, Oweis Z, Danpanichkul P, Baidoun A, Alsakarneh S, Dahiya D, Njei B. Socioeconomic and demographic disparities in the impact of digestive diseases in the middle East and North Africa (MENA) region. International Journal For Equity In Health 2025, 24: 85. PMID: 40148874, PMCID: PMC11951616, DOI: 10.1186/s12939-025-02448-9.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsEstimated annual percentage changeSocio-demographic indexAge-standardized incidence rateDisability-adjusted life year ratesGlobal Burden of DiseaseMiddle East and North AfricaGender Inequality IndexHuman Development IndexMiddle East and North Africa regionImpact of socioeconomic disparitiesIncidence rateAge-standardized mortalityAge-standardized ratesAnnual percentage changePercentage changeInfluence disease burdenBurden of DDBurden of diseasePublic health challengeHighest incidence rateSocioeconomic disparitiesDD incidenceTargeted interventionsNorth AfricaThe Role of Artificial Intelligence Combined With Digital Cholangioscopy for Indeterminant and Malignant Biliary Strictures: A Systematic Review and Meta-analysis.
McCarty T, Shah R, Allencherril R, Moon N, Njei B. The Role of Artificial Intelligence Combined With Digital Cholangioscopy for Indeterminant and Malignant Biliary Strictures: A Systematic Review and Meta-analysis. Journal Of Clinical Gastroenterology 2025 PMID: 39998988, DOI: 10.1097/mcg.0000000000002148.Peer-Reviewed Original ResearchConvolutional neural networkMalignant biliary stricturesAI-based systemsArtificial intelligence (AI)-based algorithmImage processing speedEndoscopic retrograde cholangiopancreatographyBiliary stricturesComputer visionPooled sensitivityNeural networkMachine learningDiagnostic performanceMeta-analysisIntelligent combinationIndeterminate biliary stricturesDiagnostic odds ratioImprove diagnostic yieldReceiver operating characteristic curveSystematic reviewOperating characteristics curveProcessing speedDiagnostic yieldRetrograde cholangiopancreatographyDiagnostic accuracyWorking group methodologyMortality, Hepatic Decompensation, and Cardiovascular Outcomes in Lean vs. Non-lean MASLD Cirrhosis: A Veterans Affairs Cohort Study
Njei B, Mezzacappa C, John B, Serper M, Kaplan D, Taddei T, Mahmud N. Mortality, Hepatic Decompensation, and Cardiovascular Outcomes in Lean vs. Non-lean MASLD Cirrhosis: A Veterans Affairs Cohort Study. Digestive Diseases And Sciences 2025, 70: 802-813. PMID: 39779587, PMCID: PMC11839701, DOI: 10.1007/s10620-024-08764-4.Peer-Reviewed Original ResearchConceptsNon-lean individualsAll-cause mortalityMajor adverse cardiovascular eventsIncreased risk of all-cause mortalityRisk of all-cause mortalityVeterans Health AdministrationRisk of hepatic decompensationPrevalence of diabetesRisk of cardiovascular mortalityHepatic decompensationHigher mortality riskCardiovascular-related mortalityCox proportional hazards modelsCohort study of patientsCardiovascular outcomesIncident major adverse cardiovascular eventsRetrospective cohort study of patientsProportional hazards modelNon-HispanicRetrospective cohort studyCompeting risk regressionHealth AdministrationMultivariate Cox proportional hazards modelLean individualsAssessed associationsLiver Fibrosis and Cardiovascular Events
Nso N, Bookani K, Trimingham M, Orji R, Njei B, Balasubramanian S, Pursnani A. Liver Fibrosis and Cardiovascular Events. Southern Medical Journal 2025, 118: 19-25. PMID: 39753232, DOI: 10.14423/smj.0000000000001769.Peer-Reviewed Original ResearchConceptsLiver fibrosis scoresNonalcoholic fatty liver diseaseRisk of cardiovascular eventsNAFLD fibrosis scoreCardiovascular eventsAll-cause mortalityFibrosis scoreLiver fibrosisSystematic reviewFibrosis-4Noninvasive liver fibrosis scoresLiver diseaseCardiovascular mortalityHigh risk of cardiovascular eventsNonalcoholic fatty liver disease fibrosis scoreRelevant prospective studiesSeverity of liver fibrosisNational Institutes of Health toolCardiovascular diseaseHigher liver fibrosis scoresSpectrum of cardiovascular diseasesFibrosis-4 scoreSeverity of fibrosisCardiovascular event occurrenceChronic liver disease
2024
Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status
Re V, Newcomb C, Carbonari D, Mezochow A, Hennessy S, Rentsch C, Park L, Tate J, Bräu N, Bhattacharya D, Lim J, Mezzacappa C, Njei B, Roy J, Taddei T, Justice A, Torgersen J. Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status. Pharmacoepidemiology And Drug Safety 2024, 33: e70069. PMID: 39662972, PMCID: PMC11634562, DOI: 10.1002/pds.70069.Peer-Reviewed Original ResearchConceptsProton pump inhibitor initiationHazard ratioVeterans Health AdministrationSevere acute liver injuryProton pump inhibitorsChronic liver diseaseAcute liver injuryRates of hospitalizationSafety of medicationsPPI initiativesHealth AdministrationLiver disease statusMedication exposurePharmacoepidemiological studiesMedicationConfoundingScoresReports of hepatotoxicityDisease statusHepatotoxic medicationsDrug exposurePump inhibitorsHepatotoxic drugsOutpatient initiationHepatic safetyThe burden of cirrhosis and other chronic liver disease in the middle east and North Africa (MENA) region over three decades
Al Ta’ani O, Aleyadeh W, Al-Ajlouni Y, Alnimer L, Ismail A, Natour B, Njei B. The burden of cirrhosis and other chronic liver disease in the middle east and North Africa (MENA) region over three decades. BMC Public Health 2024, 24: 2979. PMID: 39468483, PMCID: PMC11514855, DOI: 10.1186/s12889-024-20445-5.Peer-Reviewed Original ResearchConceptsAge-standardized incidence rateAge-standardized death ratesDisability-adjusted life yearsBurden of cirrhosisGlobal Burden of DiseaseDisability burdenDeath rateAge-standardized disability-adjusted life yearsPublic health effortsBurden of diseaseSignificant health challengesGender-specific interventionsLiver disease incidenceChronic liver diseaseIncident casesMENA regionHealth effortsCountry-specific trendsHealthcare systemGlobal burdenHealth challengesIncreasing burdenIncidence rateLife yearsEpidemiological trendsDiagnosis and Management of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review
Njei B, Ameyaw P, Al-Ajlouni Y, Njei L, Boateng S. Diagnosis and Management of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review. Cureus 2024, 16: e71451. PMID: 39544615, PMCID: PMC11560387, DOI: 10.7759/cureus.71451.Peer-Reviewed Original ResearchInternational Prospective Register of Systematic ReviewsSystematic reviewProspective Register of Systematic ReviewsLiver diseaseInternational Prospective RegisterPreferred Reporting ItemsFatty liver diseasePeer-reviewed studiesEnhance careSystematic literature searchSteatotic liver diseaseLifestyle changesReporting ItemsA systematic reviewIncreased clinical awarenessPersonalized therapeutic approachesNonalcoholic fatty liver diseaseLiterature searchNonobese individualsAdvanced imaging techniquesClinical awarenessPatient groupPharmacological treatmentMetabolic factorsTargeted treatmentEfficacy and Safety of GLP-1 Receptor Agonists in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Njei B, Al-Ajlouni Y, Lemos S, Ugwendum D, Ameyaw P, Njei L, Boateng S. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus 2024, 16: e71366. PMID: 39534801, PMCID: PMC11556413, DOI: 10.7759/cureus.71366.Peer-Reviewed Original ResearchRandomized controlled trialsGLP-1RAsReceptor agonistsSafety of GLP-1 receptor agonistsLiver functionLiver diseaseGlucagon-like peptide-1 receptor agonistsMeta-analysis of randomized controlled trialsSteatotic liver diseasePeptide-1 receptor agonistsControlled trialsGLP-1 receptor agonistsMeta-analysisMeta-analyze randomized controlled trialsRevised Cochrane Risk of Bias ToolAssociated with significant reductionsPromote weight lossImprove liver functionCardiovascular risk factorsCochrane risk of bias toolRisk of bias toolRandom-effects modelHepatic outcomesHepatic function markersGLP-1RAS2281 Non-Cardia Primary Squamous Cell Carcinoma of the Stomach Is Extremely Rare and Shows Poor Survival
Protiva L, Ketwaroo G, Njei B, Protiva P. S2281 Non-Cardia Primary Squamous Cell Carcinoma of the Stomach Is Extremely Rare and Shows Poor Survival. The American Journal Of Gastroenterology 2024, 119: s1634-s1635. DOI: 10.14309/01.ajg.0001038492.00710.80.Peer-Reviewed Original ResearchS3554 Safety and Efficacy of Overtube-Assisted Percutaneous Gastrostomy Tube Placement in Patients With Head and Neck Cancer: A Case Series
Saha S, Ketwaroo G, Ogurick A, Njei B, Protiva P. S3554 Safety and Efficacy of Overtube-Assisted Percutaneous Gastrostomy Tube Placement in Patients With Head and Neck Cancer: A Case Series. The American Journal Of Gastroenterology 2024, 119: s2353-s2354. DOI: 10.14309/01.ajg.0001043584.46794.74.Peer-Reviewed Original ResearchS3535 Unusual Complication of Percutaneous Gastrostomy Tube Replacement
Liang S, Ketwaroo G, Njei B, Ogurick A, Rabiee A, Protiva P. S3535 Unusual Complication of Percutaneous Gastrostomy Tube Replacement. The American Journal Of Gastroenterology 2024, 119: s2341-s2341. DOI: 10.14309/01.ajg.0001043508.94655.75.Peer-Reviewed Original ResearchS2187 Disparities in the Burden of Digestive Diseases in the Middle East and North Africa (MENA) Region
Al Ta'ani O, Al-Ajlouni Y, Alhalalmeh Y, Almasaid S, Njei B. S2187 Disparities in the Burden of Digestive Diseases in the Middle East and North Africa (MENA) Region. The American Journal Of Gastroenterology 2024, 119: s1563-s1563. DOI: 10.14309/01.ajg.0001038116.67375.df.Peer-Reviewed Original ResearchS1927 Sounding the Alarm on Lean MASLD in US Adults: Insights From NHANES 2017-2020
Njei B, Boateng S, Mohamed M, Al-Ajlouni Y, Dranoff J, Lim J. S1927 Sounding the Alarm on Lean MASLD in US Adults: Insights From NHANES 2017-2020. The American Journal Of Gastroenterology 2024, 119: s1380-s1381. DOI: 10.14309/01.ajg.0001037076.71899.13.Peer-Reviewed Original ResearchS2118 Association Between Congenital Birth Defects and Development of MASH Cirrhosis: Insights From the National Inpatient Sample
Boateng S, Ezeani C, Ameyaw P, Njei B. S2118 Association Between Congenital Birth Defects and Development of MASH Cirrhosis: Insights From the National Inpatient Sample. The American Journal Of Gastroenterology 2024, 119: s1512-s1513. DOI: 10.14309/01.ajg.0001037840.47400.fc.Peer-Reviewed Original ResearchS1894 The Burden of Liver Cancer in Sub-Saharan Africa: An Analysis From the Global Burden of Disease Database
Al Ta'ani O, Al-Ajlouni Y, Alhalalmeh Y, Almasaid S, Muzammil T, Daniel T, Njei B. S1894 The Burden of Liver Cancer in Sub-Saharan Africa: An Analysis From the Global Burden of Disease Database. The American Journal Of Gastroenterology 2024, 119: s1361-s1361. DOI: 10.14309/01.ajg.0001036944.57871.17.Peer-Reviewed Original ResearchS2086 Outcomes After Major Adverse Cardiovascular Events in MASLD Patients: A Nationwide Inpatient Sample Study
Ameyaw P, Boateng S, Boampong A, Ugwendum D, Zinyandu T, Opoku I, Ahmed A, Njei B. S2086 Outcomes After Major Adverse Cardiovascular Events in MASLD Patients: A Nationwide Inpatient Sample Study. The American Journal Of Gastroenterology 2024, 119: s1489-s1490. DOI: 10.14309/01.ajg.0001037712.96310.7f.Peer-Reviewed Original ResearchS1828 Cumulative Social Risk Exposure and Risk of Lean MASLD in US Adults: NHANES 2017-2020
Boateng S, Ameyaw P, Kasar A, Njei B. S1828 Cumulative Social Risk Exposure and Risk of Lean MASLD in US Adults: NHANES 2017-2020. The American Journal Of Gastroenterology 2024, 119: s1318-s1319. DOI: 10.14309/01.ajg.0001036680.52638.2f.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply